Novel Receptor-Targeting Radiolabeled Peptides for Cancer Imaging
Sep 5, 2023
Novel Receptor-Targeting Radiolabeled Peptides for Cancer Imaging
Yubin Miao
October 11, 2012
All right, I think we are going to start.
My name is Raghush Dobrakian.
I'm Director of Molecular Imaging Laboratory
at Beckman Institute and running Nuclear Imaging Laboratory.
And we don't have too many such talks about the nuclear imaging
technology.
And today, we have a special guest, which is Yubing Miao.
He's an Assistant Professor in College of Pharmacy
in the University of New Mexico.
And he will be talking about the novel receptor-targeting
radiolabeled peptides for cancer imaging.
So we got kind of a theme with an interest of cancer imaging.
And today, we'll be talking about the radiolabeled
peptides for imaging cancer.
And just a brief biography, Dr. Miao
received his PhD in radiopharmaceutical chemistry
from Beijing Normal University.
And he did the postdoctoral training
at the University of Missouri, Columbia.
And right now, he's the Assistant Professor
working with the SPECT PET imaging of cancer
to detect with the radioactive peptides
to detect primary and metastatic tumor lesions non-invasively.
So I'm very glad to have him here.
Please greet him before the presentation.
Thank you so much for your kind introduction.
It's my great pleasure to be here and share with you
our work on novel receptor-targeting
radiolabeled peptides for cancer imaging.
So in this talk, I'm going to have four sections.
In the first section, I'm going to give you
a brief introduction on principle
of molecular imaging of cancer.
Then I'm going to give you two sets of examples.
But basically, one set example will
be targeting the GnR2 receptor for breast cancer imaging.
Then give you two generations of the peptides targeting
the MC1R for melanoma imaging.
So let me start with the principle of molecular imaging
of cancer.
So as we know, to perform molecular imaging,
you need to have three components,
namely molecular target, imaging probe, and imaging modality
here.
So both intracellular or cell surface targets
can be used as molecular targets.
Compared to the intracellular target,
there is an advantage associated with the cell surface target.
That is, the radiolabeled probe or imaging probe
doesn't have to penetrate the cell membrane to reach target.
Once you determine the molecular target,
then you need to have imaging probe specifically
bind to the target.
And general signals for different type of imaging
modalities here.
So normally, antibody, peptide, or some molecules
can be used as imaging probe, depending
upon which imaging modality you're going to use.
You need to label this imaging probe either with radionuclide
or SPECT PET imaging.
Or you can label with the optical tags for optical imaging.
So in today's talk, I'm going to focus on radionuclide imaging,
basically the SPECT and PET.
I think I'm going to focus on the SPECT.
So by definition, SPECT means single photon emission
computed tomography.
And PET means positron emission tomography.
This slide shows you the peptide receptor binding specifically
we use in our projects.
So basically, you can see the receptors are overexpressed
on the cancer cells.
And you can use peptide to specifically deliver
either diagnostic, radionuclide, or therapeutic radionuclide
to bind to the receptor for cancer imaging and treatment.
And as you can see, peptide, the radionuclide
can attach to the peptide through a linker.
So different type of linkers can be used to optimize
the binding affinity of the molecule,
as well as modifying the biodistribution properties
of the molecule.
So once you inject the radiolabeled peptides
in a bloodstream, through the blood circulation,
the peptide itself can specifically find the receptors
on the cell surface and then bind there.
So you can generate, the peptide can generate signals.
Radiolabeled peptide can generate signals
for spectrum head imaging.
This slide gives you an idea about how a radiopharmaceutical
can essentially find the targets and accumulate
in the tumor sites in the body.
So basically, you need to inject a radiopharmaceutical first
into a patient through the vein.
Through the blood circulation, the drug will distribute
throughout the body of the patient.
And as time goes on, the drug clears
from the non-tumor tissue rapidly
because there's no target available
for the radiopharmaceutical to find.
And eventually, the radiopharmaceutical remaining
in the body is retained in the tumor site
because the peptide will find the receptor and bind there.
This slide gives you an idea
about the clinical imaging process.
First of all, you need to inject a radiolabeled imaging probe
into a patient, and after a certain period of time,
the patient will lie down under the camera
with the data collection key.
And the data collection can be converted to,
can generate a lot of projections here,
and through the reconstruction process,
it can generate tomograms here.
Now, the radiologists will come and look at these pictures
and diagnose the disease.
So now, the question is, can we do this type of imaging
in a small animal?
The answer is yes.
So here, I show you the nanospec CT available in our college
which can be used for the small animal imaging.
So as you can see, this machine is not too big.
It's about one meter wide and 1.6 meter tall.
And we can use for mice imaging, rats, and rabbit.
I think we may be able to do small monkey as well
by changing the size of this hole.
And here, it shows you two examples
using the imaging probe developed in my laboratory
for the primary melanoma imaging
as well as the pulmonary metastatic melanoma imaging here.
So as you can see, to generate such specific cancer images,
you need to have a receptor targeting
or cancer-specific imaging probes.
We also have a lab pet, small animal imaging pet
we can use for pet imaging.
Here gives you example by using F18-FDG
into a small mouse to detect
the pulmonary metastatic melanoma imaging here.
So you can easily, through the CT image,
you can see the spot here.
And this is a necropsy picture of the lung.
And essentially, the F18-FDG can detect this spot
as the lung mass here.
But despite the success of F18-FDG,
you can see F18-FDG can generate
a very high background here.
The reason for that is F18-FDG
is not a cancer-specific imaging agent, okay?
The elevated uptake of F18-FDG in cancer cells
is because cancer cells normally have higher
energy consumption compared to normal cells, okay?
So now, let me give you a couple examples
about how to target the gonadotropin-releasing hormone
GnRH receptor for breast cancer imaging.
First of all, I'd like to give you
a brief introduction of breast cancer.
And the breast cancer is the most commonly
diagnosed cancer in females.
And the second is second-leading cause
of cancer-related death among women in the United States.
About 209,000 new cases were diagnosed,
and about 40,000 cases of death
occurred in the United States in 2010.
And normally, we use mammography to detect breast cancer.
And mammography is a very effective detection tool
for the primary breast cancer.
However, it cannot detect the metastasis of the breast cancer.
And F18-FDG, as I briefly mentioned,
is also a most commonly used PET imaging agent
for the cancer detection, including breast cancer.
So basically, F18-FDG can be also used
for some other cancer detections.
And F18, like I mentioned, F18-FDG
is not a cancer-specific agent.
So it has limited applications
in detecting breast cancer metastasis,
because of the lack of specificity.
And in this project, we're interested
in to use GLH receptors targets
and to develop imaging agents.
And because these GLH receptors are overexpressed
on the breast cancer cells, and as well as overexpressed
on the human breast cancer samples.
And very importantly, the GLH peptide
can bind to the GLH receptors with nanomodal binding agents,
making it feasible to use peptide
to specifically deliver imaging isotope
for breast cancer imaging.
So as you can see here,
this is a native GLH peptide sequence.
And both N-terminals and C-terminals
are involved in the GLH receptor binding.
So if you want to attach a metal chelator
to this molecule for radiolabeling,
basically you don't want to attach
either N-terminals or C-terminals,
because both are very important for the receptor binding.
So our hypothesis was the GLH peptide
can specifically bind to the GLH receptors
on the human breast cancer cells,
and we can use it to deliver some diagnostic,
radiolabeling, specifically Indian-111,
to breast cancer cells for breast cancer imaging here.
So as you can see,
because both N-terminals and C-terminals
are involved in the receptor binding here,
therefore we choose to conjugate
metal-radio-metal chelator here
through the D-lysine here, either through a linker.
As I mentioned, different linkers can be used,
either to optimize the binding affinity,
as well as modify the bio-distribution properties
of the whole molecule.
So first of all, to do the proof principle studies
we designed three peptides,
tried to answer this question,
because the lysine has two amino groups,
alpha amino group and the epsilon group, amino group.
So the first question when we tried to synthesize peptide
was which group is better?
We don't know that.
Therefore, we kind of put the metal chelator
through the linker, either on the epsilon amino group
of D-lysine or on the alpha amino group of D-lysine.
And we also compare, switch the D-lysine to L-lysine
to see if the configuration
can also affect the binding affinity.
So essentially, by evaluating the three peptides,
we want to answer the questions,
which amino group is the best in terms of the delta power.
Here it shows you the peptide synthesis
and the identification here.
Essentially, I'm not going to focus
on the chemistry part here.
Essentially, we use F-mode chemistry
to synthesize a peptide.
Here, I'll just give you one example,
which is DOTA, A-H-X, D-lysine-16 and H-1.
So essentially, we conjugate the metal chelator DOTA
to the epsilon amino group of D-lysine
through the A-H-X linker here.
And after the peptide synthesis,
we use HPLC to purify that
and also use mass spec to identify the peptide.
Then the next thing you want to do is,
the next question you want to answer is
if the conjugation of the DOTA metal chelator
really affects the binding affinity of this molecule or not.
So essentially, we did a competition study here,
competitive assay study here.
And essentially, you can see three peptides
display different receptor binding affinity, essentially.
And the DOTA G and H-1, which was the link,
the metal chelator was conjugated to the
epsilon amino group of D-lysine through the A-H-X linker,
displayed the highest receptor binding affinity here,
which was about 36.1 nanomolar.
So essentially, through this in-vitro study,
we can conclude the conjugation of DOTA
to epsilon amino group of D-lysine
to maintain the nanomolar receptor,
G-H receptor binding affinity.
So after that, we just focused on that peptide
because it displayed 36.1 nanomolar binding affinity.
Here shows you how to prepare indium-labeled compounds.
So you want to put a re-denucleotide to the peptide now
for essentially, you can do spectrometry.
The synthesis procedure is pretty straightforward.
Basically, you can put the peptide,
re-denucleotide in a buffer,
and incubate it 75 to 45 minutes.
Then through the HPLC purification,
we get a very single peak here for the imaging.
And just to remind you,
the decay properties of the Indium-O11.
Indium-O11 is a good speck imaging iso.
It's being widely used in the clinic,
in nuclear medicine department.
And it has a 2.83 days half-life.
When Indium-O11 decays, it can generate two gamma rays,
171 and 245 KeV gamma rays.
You can be used for the imaging purpose.
And by the way, an Indium-O11 is commercially available.
So you can easily just order from Nordeon
or Peking Alba, maybe, to do your study.
Another important parameter we need to determine
is serum stability.
So you want to make sure the peptide you designed
is stable enough for them to find the receptor,
to bind to the receptor.
So here it shows you the stability of Indium labor.
So the AHX, GnRH1 here.
This is a QC after the HPLC purification.
And this is two-hour serum stability data.
This is 18-hour serum stability data.
So pretty much, as you can see,
this peptide was stable in the mouse serum.
It's 37 degree up to 18 hours.
And we also want to show the specificity
of this tracer to bind to the GnRH receptor listed here.
So as you can see, without a peptide block,
with the peptide blockade, the binding to receptors,
GnRH receptor can be blocked by 85% here.
So if you put a code peptide to block the receptor sites,
then the binding drop down to about 15% of the original one.
Demonstrating this tracer,
even after you label it with Indium-11,
can still display GnRH receptor-specific binding.
Now, this slide shows you the GnRH receptor expression
on both cells and the xenografts.
So we choose MDAMB-231 human breast cancer cells
as cancer cells to generate animal models
to further evaluate the bio-distribution properties
of the radio tracer.
So as you can see here,
GnRH receptors over-express both on the cells
and the tumor xenografts in here,
making it a suitable model for us
to evaluate a tracer we develop.
This slides you to the bio-distribution
of this Indium-Delta GnRH1 here.
And as you can see,
this tracer display a very fast tumor update here.
0.5-hour post-injection,
it reached about 1.8% ID per gram in the tumor.
And to demonstrate possible,
we can use this one for the cancer imaging here.
Then we further determine the human breast cancer imaging
using the SPECT-CT we have,
and use this probe to do the imaging studies.
And as you can see here,
we did this study with one over-post-injection.
Basically, you inject the tracer into the mouse
through the tail vein,
and one over-post-injection for the mouse
on the SPECT-CT to collect all these images.
So you can see the backbone of the mouse
collected from the CT, by CT.
So it provides you the anatomic information
of the whole mouse.
And then all this colorful information is from the SPECT.
Can provide you the functional information of that tracer.
So essentially you can see,
by using this tracer,
you can clearly see the MDM-B231 human breast cancer here.
And also, you can see the urinary clearance here,
as well as some kind of liver uptake here.
So this is two organs we're trying,
now we're working on,
trying to decrease down the uptake
either in the kidney and liver.
So hopefully we can reach this conclusion.
The delta-position display important factor,
is an important factor on the binary feeding
of the GIH peptide.
So essentially the coupling of the delta
to the epsilon in a group,
is essential to remain the manual binding
and feeding of the GIH peptide.
And the successful imaging of this human breast cancer
genographic tumor lesions,
using the imaging probe we developed,
provide kind of a platform for us to develop further,
you know, more imaging probes
that would improve the bio-distribution properties.
Now let's switch gear to another type of cancer,
so, which is melanoma.
In this type of cancer, we're using different receptors.
So basically I'm going to give you the second example,
by targeting G-protein carboreceptors
you can use for cancer imaging.
A brief introduction on melanoma.
So melanoma is number six,
commonly diagnosed cancer in the United States.
And one out of the 75 Americans,
will eventually develop this disease during their lifetime.
And in fact, one person dies in an hour in the United States
because of the malignant melanoma.
And about 68,000 new cases was diagnosed,
and about 8,700 cases of death occurred in the United States
in 2010.
And we're very interested to develop an imaging agent
as well as a therapeutic agent for this cancer,
because there's no curative treatment available
for metastatic melanoma.
And also melanoma specifically,
compared to other types of cancer,
is more resistant to the conventional chemotherapy agents.
We've been using melanoclonin-1, MC-1 receptors as targets,
because this receptor overexpressed
on both human and mouse cells.
And as you can see, it's a G-protein carboreceptor
with seven transmembrane domains here.
And very importantly, the alpha melanocytes
stimulating hormone peptide and many of its analogs
can bind to these receptors, like shown here,
as nanomolar or subnanomolar binding impurities.
Therefore, we're very interested in using
the alpha-MSH peptides to deliver imaging isotope,
and eventually deliver therapeutic isotope
for melanoma treatment as well.
Let's look at the Y-type alpha-MSH peptide.
So Y-type alpha-MSH peptide is a peptide
with 13 amino acids here.
And the amino acids contain a massive sequence
for receptor binding.
So you have to keep this four amino acids there
for MC-1R binding.
As well, in this same order.
It's very important.
And the NDP-MSH is a gold standard
for in vitro binding studies,
because this peptide has subnanomolar binding
with the MC-1 receptors.
And several groups have tried to label this peptide,
linear peptide, with radionuclides for melanomotarity.
And unfortunately, the success was limited,
majorly because of the in vivo stability of linear peptide.
So one way to improve the stability,
in vivo stability of the peptides,
is to cyclize the peptide.
So this slide gives you an idea
about different cyclizations have a different effect
in terms of tumor uptake and kidney uptake here.
And the three peptides listed here,
the first one is Theta-CC-MSH.
So you can see this peptide is a linear peptide.
And second one is Theta-C-MSH.
The peptide was cyclized by the disulfide here.
And essentially, the third one is a metacyclized peptide.
Now, if you look at the bio-attribution data
to our post-injection,
you can see the linear peptide displayed
moderate tumor uptake here,
about 5.9% ID per gram to our post-injection.
And the kidney uptake was high,
about 63% ID per gram to our post-injection.
Now, when you switch to the disulfide-cyclized peptide,
which is peptide two,
the tumor uptake was slightly higher,
better than the first one, linear.
Very important, if you look at the kidney,
you can see the kidney uptake dropped almost 50%,
40, 45% probably.
And essentially, the medium-cyclized peptide
displayed the best, the highest tumor uptake.
Here is about 17.3% ID per gram.
And very importantly, you see the kidney uptake
further dropped to 8.7%.
So this two studies demonstrating
you can use peptide cyclization
to improve the tumor uptake
and also affect the normal accumulation
of the tracer to the normal organs.
And also different cyclizing strategy has different effect
in terms of the tumor uptake and the renal uptake here.
So in my lab, I'm very interested
about using lactam bridge to cyclize the peptide.
The reason for that is metal cyclization
displayed very high tumor uptake.
The synthesis is a little complicated.
You need to put the metal in it after the peptide synthesis.
Alternatively, if you use lactam bridge cyclization,
you can finish this cyclization easily
during the peptide synthesis.
So specifically, the first generation,
we're more focused on designing the peptide like this,
more close to the structure of native peptide,
alpha-MSH peptide.
You can see we kept the MC1 binding sequence here,
and the peptide was cyclized
by a lysine-aspirin lactam bridge here.
And the delta is a good metal chelator,
so a conjugated delta to the peptide
either through a linker or without a linker.
So when you compare the by distribution
of these two molecules,
you can see the effect of the linker on tumor uptake
and also normal organ updates.
And the third one we were interested in,
if the delta position can really affect
the binding of tumor uptake or renal uptake as well.
So we conjugate the delta here instead of this side.
And then also you can use this,
you can label this peptide with indium 1F.
Okay, now to evaluate the exact by distribution properties
of the radio tracer,
we specifically established two models.
This is one of the model,
E16F1 with a normal mouse model.
Essentially, this model is designed
to mimic the primary melanoma development.
So what we did was we inject a million E16F1 cells
subcutaneously in the right flank of the mouse.
And after nine to 10 days,
the tumor will reach about 0.2 grams here.
And then you can use for by distribution
or you can use for imaging studies.
Okay, now here shows you the by distribution
of melanoma imaging with this indium delta glycolysis H.
As you can see, this peptide has very high tumor uptake.
It's very high MC1 binding affinity,
about 0.9 nanomolar here.
And you can easily see the tumor lesions
can be easily visualized here using this tracer
as imaging probe by spec CT images here.
So here's kidneys and here's the bladder.
So you can easily see the urinary excretion pathway
of this peptide.
So specifically, just to remind you,
we have a full by distribution published in this paper.
Just extract the information from that paper.
The tumor uptake was about 10.4% ID per gram
two-hour post-injection.
And renal uptake was about 13.1% ID per gram
at two-hour post-injection.
So this study demonstrated
that actin-Bridge cyclase can also work.
It works, it can be used to cyclize a peptide
for a good melanoma imaging.
Oh, so I didn't include the other peptide,
which was indium delta CYC MSH without linker.
So essentially, this peptide with the linker
has a little higher tumor uptake compared to that one.
And the kidney uptake was less
than the peptide without linker.
Here shows you the other peptide.
We conjugate delta at the different position here.
And also, the binding affinity was high, 0.6 nanomolar.
And you can easily see the tumor lesions here as well
by using this imaging code for SPECT-CT images here.
And specifically, if you look at tumor uptake,
it was a little slightly higher, but comparable.
11.4% ID per gram at two-hour post-injection.
And surprisingly, we had a very high kidney uptake here
compared to the previous one we talked.
It was about 60.5% ID per gram.
So essentially, even what I'm going to,
the taking-home message is,
even if you have a very similar binding affinities,
you can't really use imaging data
to predict what's a tumor uptake
or the normal organ accumulation would be.
So the bio-distribution study is necessary.
So now, you may ask me a question.
Can you do some other, can you label the peptide
with some other imaging isotope?
The answer is yes.
So this gives you an example.
Basically, we can switch Indium-111 to Gallium-67,
which is also a SPECT imaging isotope here.
So also, by switching Indium-111 to Gallium-67,
this peptide also displayed a good tumor uptake here,
about 12.9% ID per gram at 12-hour post-injection.
You can easily see tumor lesions clearly here.
But compared to the Indium compound we just talked about,
the kidney uptake was a little higher.
So it's about 27.6 ID per gram at 12-hour post-injection.
And another potential application for this study is
you can easily switch this Gallium-67
to Gallium-68, which is a generator-produced
peptide isotope for the peptide imaging.
Okay, I mentioned we established two models.
So another model is P16F10, metastatic melanoma model,
trying to mimic the metastasis development in human.
What we did is we inject these melanoma cells
into a mouse through the pelvic,
trying to mimic the cancer cells detached
from the primary site, not get into the bloodstream,
through the blood circulation,
try to establish metastasis in some other organs.
So essentially, because we inject into the tail veins,
the blood will pump back to the heart,
then pump it out, and leave,
actually the lung will be the first organ
to develop the metastasis.
But as time goes on, if time is long enough,
you can still see metastasis either in the bone,
liver, adrenal gland, and some other organs.
So here shows you the left,
left panel shows you the CT image of a normal mouse,
and after the CT image, we took out the lung here.
So here shows you a proxy picture of a normal lung here.
And the right side shows you a CT image
of a mouse-bearing lung metastasis, okay?
And this is the lung we took out after the CT image.
So if you look at the CT image,
you can see for the normal mouse,
the lung was functional, 100% functional.
You see a lot of air in the lung area,
back area here.
But for this mouse-bearing lung metastasis,
the lung function was not 100%.
So you see some of the lungs still working,
but most of them didn't work.
You don't see a lot of air in the lung area.
So in other words, you can use micro-CT
to monitor the development of the metastasis.
Okay, now, so to answer the question,
if we can use imaging probe to detect metastasis,
we need to study with our imaging probe.
And meanwhile, we try to answer the question,
how good it is compared to the F-18 FDG?
So essentially, we inject melanoma-bearing mouse
with the F-18 FDG first.
First day, we inject it in,
and then we collect the PET imaging of this mouse.
After study, we took the mouse and put it back in the cage,
waiting for another day.
So the reason for that is we try to wait the F-18 decay.
So half-life for F-18 is two hours.
So after a day, it decayed away.
And then we took the same mouse back
and inject it with the imaging probe.
We developed it here and used SPECT imaging
to collect the SPECT imaging,
and then compare to see how easy
or hard we can find the metastasis.
So as you can see, you can see the accumulation
of the activity in the lung area by the F-18 FDG image,
but you cannot easily see the individual spots
developed here.
On the other hand, the SPECT imaging
using the indium probe we developed,
we can easily see all these spots developing in the lung,
the melanoma metastasis here.
So indicating the small animal model
in our receptor and imaging probe
is better than the F-18 FDG
to pick up all this small metastasis developing in the lung.
And in another study we also conducted
was we tried to compare
two animals bearing metastatic melanoma
to see if we can use it to monitor the development.
So essentially, this mouse
was 20 days post-cell injection here.
As you can see, as time goes on,
you have more metastasis develop here.
Also, the lesion kind of became bigger here.
In other words, what we tried to demonstrate is,
if you start a chemotherapy
or some other therapy treatment here,
sorry about that.
So if you start a treatment,
then you can use this imaging probe
to monitor the therapeutic response
to see the shrinkage of the lesions.
And then we further did a study to try to answer
how early we can use this imaging probe
to detect metastasis.
So I've shown you the 17 days development
and 20 days development.
This study we did was 13 days post-IV injection.
So you can see there were only five individual spots
in the lung.
And by using the imaging probe,
we can also clearly detect this metastasis here.
And this is F18 had imaging at 16 days post-development.
Okay, let me talk about the second generation
of the lactobacillus cyclites peptide for melanoma imaging.
So if you still remember the bio distribution,
I showed it in the early slides.
One question we have after we kind of develop
a first generation peptide was,
the tumor uptake for this peptide
was not as high as the metacyclized peptide.
So the metacyclized peptide displayed 17.3%,
IV program 12 post-injection.
And the tumor uptake for the first generation peptide
is about 10.4%.
So one question was,
we have demonstrated lactam bridge cyclization work.
We can still develop this type of peptide
for melanoma targeting.
But the question was,
can it be as good as metacyclized
or can it exceed the metacyclized peptide?
So we just simply looked at the structure
and said, okay, the direct difference is the cyclization.
The cyclic moiety is different.
So for this one, we have 12 amino acid in this moiety
and the metacyclized, we only have eight.
So we said, why don't we just try a smaller one?
We don't know if the size is an important factor
at that time.
And what we can do is just cyclize,
we just kept the MC1 binding sequence here.
Well, how about just cyclize it directly
using this ASP less lactam bridge?
So that's what we did.
But we were not sure if this is good or not.
But after the in vitro binding assay,
we said, okay, it's good.
We're worried about this kind of a cyclization
may affect the binding region very badly.
So in terms, after we got the binding affinity here,
oh, it's still good.
1.8 nanomolar binding affinity
is still kind of a very high binding affinity.
So this is a peptide I just talked about.
And meanwhile, we try to use different type of linkers
to answer two questions.
First is, we don't know if the NLE moiety,
NLE cyclic moiety is very important or not.
Can we insert amino acid in it
to modify the biodistribution properties?
Or we have to insert amino acid between DOTA and the NLE
instead of this between NLE and the cyclic moiety.
So we synthesized two peptide and determined IC50.
It was interesting to see,
actually, it's not a good idea
to insert the amino acid linkers here
to separate NLE and the cyclic moiety.
Because if you did that,
the binding affinity dropped to 873 nanomolar.
But if you move the amino acid linker
more towards the DOTA,
then the binding affinity comes back at 11.5 nanomolar.
And also, we did this peptide,
if you change this blue amino acid to glycine,
the binding affinity come back around 2.1 nanomolar,
very close to this peptide without NLE.
Therefore, we decided, okay,
let's do the biodistribution for those two peptides to see.
So here shows you the biodistribution and imaging
of this enium DOTA NLECYC-MSH-Hex.
So basically, we don't have any
more amino acid linker here.
After we saw the biodistribution, we were thrilled
because if you look at the tumor update,
now it's 19.4% in the gram-12 host in here,
even slightly higher than the metacycline peptide.
So it seems like the smaller ring kind of works better
compared to the bigger ring in terms of the tumor targeting.
And importantly, if you look at the kidney update,
now it dropped to 9.5%.
So in other words, it increased the tumor update,
also decreased down the renal update.
And now, you can see from the image,
the contrast is better than the first-generation peptide here
and you can easily see the lesion,
flank lesion clearly here, okay?
If you look at the tumor-to-kidney-alpha-beta ratio
compared with the metacyclized peptide
in the first-generation,
you can better understand the improvement
by switching to the second-generation peptide here.
So the blue columns are enium DOTA glycolysis MSH,
which was first-generation.
And this green columns are metacyclized peptide.
Yellow columns are second-generation peptide without linker.
So essentially, you can see by switching
to this second-generation peptide,
it displayed comparable high tumor-to-kidney-update ratio
compared to the metacyclized,
very comparable with metacyclized peptide.
So here's you see the biorespiration of the other peptide
with the GG linker,
with the similar binding affinity, 2.1 nanomolar.
And you can see the tumor-update was high as well.
So about 18.5% ideal gram at two-hour post-injection.
Very importantly, all this normal organ accumulation
were lower than 1.5%, I would say.
And importantly, you see the kidney-update now
is about 7.5%.
So even further lower than the peptide
without the glycolide linker.
And you can easily see the melanoma lesions clearly
with all these individual spots here.
A lot of more information.
So this slide shows you the comparison
in kidney and liver update
between the peptide with GG linker or without GG linker.
So basically, the blue curves
are Indian peptide with the GG linker in it.
So quickly, you can see by insert this GG linker,
it decreased down the renal update about 1.3%, 30%.
And the liver update was decreased about 2.3%, 60%.
Now, if you look at the tumor-to-kidney ratio,
tumor-to-liver update ratio,
it's another way to really see the improvement.
So by insert a glycolide linker,
you kind of increase the tumor-to-kidney update ratio
as well as tumor-to-liver update ratio here.
So this is very important
because one of the directions we want to work
with this peptide is to try to use the peptide
to do the treatment.
So you can easily switch diagnostic,
radionuclide to therapeutic radionuclide.
For the therapeutic perspective,
then the ratio is important.
You want to deliver the maximum dose to the tumor
and the minimum dose to the normal organs, right?
So the improvement in tumor-to-kidney ratio,
tumor-to-liver ratio were significant.
So in conclusion,
so we have developed two generations
of the MC1 receptor peptides,
both primary and metastatic lesions
will be visualized by the first generation peptide.
And I didn't show you the peptide distribution
of the peptide without linker,
but basically the increasing the overall active charge
of the peptide could significantly reduce the renal uptake
of the peptide without affecting the tumor uptake.
And we found the reduction of the peptide size
essentially contribute to the tumor uptake,
increase the melanoma uptake
of the second generation peptide,
also decrease down the renal uptake.
Amino acid linkers exhibited profound effects.
So if you look at the peptide with the glycolytic linker
or without glycolytic linker,
you can easily see by insert the amino acid linker,
you can further decrease down the renal uptake
as well as the renal uptakes.
So I'd like to thank the postdocs
and graduate students working in my lab
and the collaborators in our cancer center
and the financial support to this project.
And I'd like to thank you for your attention.
I'd be happy to answer any questions.
Yes?
Can you mention that you could just take an image
and then have things decay
and then keep injecting them to penetrate?
Is there no negative side effect
of having these two effects?
So you're talking about the study we did
with the amphetamine FDG and the EDM micropeptides.
So one thing I'd like to get your attention
is amphetamine FDG, the targeting mechanism
is different with the peptide we injected in.
So amphetamine FDG is not targeting the MC1 receptor.
So basically the elevated uptake
is because cancer cells has higher antigen production.
And the peptide we developed there is targeting the MC1.
So I assume there's no cross effect between those two agents.
So another thing is if you want to do the dynamic image
over days, you can select the imaging nucleotide
diagnostic nucleotide with longer half-life.
So you can, for example, even this EDM peptide
you should be able to do it, half-life is about three days.
So I'm sure you can do 24 hours post-injection.
Same mouse, if you inject this probe,
you see the 1 over 12 image and then you can put it back
and then come in 24 hours.
The only downside is if the peptide is too quickly
to clear out the body, then you will lose activity.
Or you can inject a little more to make it last longer.
Yes?
Focusing a lot on minimizing the kidney uptake
so that the signal will be lower,
have you ever gotten to the point where
the signal is low enough that if the tumor
has a size like around the kidney or near the kidney
can you distinguish tumor just from kidney signal?
That's a good question.
Actually, in this case, because the peptide size,
so the excretion pathway is through the urinary system
through the kidney.
The kidney uptake was not receptor-mediated.
We have done a blocking study to show
you can block the tumor uptake
but you cannot block the renal uptake.
So it's not specific.
So in terms if you have some metastasis in the kidney
in this case, I don't think we can use this agent
to differentiate that because the high,
you know, very kind of a high uptake in the kidney.
The reason we want to reduce down the kidney uptake
is more focused on the therapeutic structure.
So in this case, if you switch to a therapeutic
where you want to deliver maximum dose to the tumor
or less dose to the kidneys to avoid toxicity.
So just to follow up, the kidney uptake
you say is not specific but it contains in the kidney
longer than normal.
Is the kidney affecting that?
There are several factors affecting the kidney.
First of all, it's not MC1 receptor-mediated.
And the charge has been a major factor
contributing to the kidney uptake.
So for example, in this case, if we inject
some positive triglyceride amino acid
like lysine or arginine, it can block
the renal uptake up to 75% on the basis.
And also, recently some of the paper published
talk about some of the also receptive kidney evolving
with the broad spectrum, kind of a,
so we didn't know exactly how this MC1,
this peptide kind of interacted.
Do you think it may be some receptor-mediated process
but not the...
Not the MC1R receptor-mediated process, yeah.
Charge is a major factor.
So normally we use charge to,
we use positive triglyceride amino acid to block.
You can successfully block up to 70% of the uptake.
So when you've got lower kidney uptake
proportion C, usually what happens is...
So actually most of the activity in the kidney up,
on the cortex area, not the inside.
So I think for that it's just
maybe charging the gravitators.
So the positive charge for the peptide side
can interact with the negative charge of the kidney side.
Yes.
The structure of your region, or non-region,
does it affect the stability of the immune system?
No.
No, you're very stable.
Yeah, so what happens is for the linear peptide,
like an NDP peptide, you can label with the DOTA.
You put the DOTA there and label with Indian 0.11.
And what happens is enzyme can kind of find
the amino acid and chop it up.
So the peptide itself don't have enough time to deliver.
That's why you have the D times.
Yes, you can, another way, I didn't mention,
you know, cycloaddition is one way,
but you can switch from natural amino acid
to D amino acid.
It can also help increase immune stability.
Because when you switch from L configuration
to D configuration, enzyme has hard time
to really recognize that and chop the peptide.
Yes.
I would like to go back to the study
where you compared the head and speck image
of the pulmonary metastasis.
And you suggested that the speck,
those speckles on the speck,
they are of the metastatic cells, right?
So did you try to develop an audiography
just to make sure that it's really what you're observing?
Because, you know, from my experience,
the speck image very often that you're doing
in this direction produces the speckles,
which are nothing real, they are just some artifacts.
We did that study.
So we use audiography as well as we take the lung out,
put on a piece of paper, lie out,
and do the speck imaging for that as well.
So we do that imaging, identify all these spots
that we need to see.
We did that as well, audiography and speck imaging as well.
And the second question I had is,
the first study will be another from the receptor.
So you showed that the speck image,
but also those receptors are expressed
in breast and lymphocytes,
and also on the prostate and also on the ovaries.
And I didn't see those actually organs.
You're right, so this GI receptor
not only just overexpress breast cancer cells,
also prostate, and the mice we use,
first of all, we use the female mice.
So in the ovaries.
Yes, you're right.
But for image, we didn't see the update there,
but unfortunately, we didn't really take
out the ovaries account.
So from bio-inspection, we should be able to see that.
But we didn't do that study at that time.
Maybe it's the question of the contrast.
Might be.
Is it expression levels?
Yeah, maybe the, yes, John, that's a good point.
The expression level may be different as well,
but we haven't really focused on ovarian cancer yet.
But it's been reported.
I think one of the cell lines
that's used for the,
this ovary three can be used for this GI receptor.
It reported the expression.
But the level, I don't have the detailed data
about the, compared to this.
Is that cancer cells over there?
Yeah.
One more.
When you switch the, from Indian to Ghanian,
what's your, decrease the chelate update?
Increase.
Increase, but, so,
it's not an issue in the chelate study?
Because Indian and Ghanian.
No, normally when we switch isotopes,
sometimes you don't see any difference
in terms of renal update or kidney update.
But sometimes you do see,
either in the tumor update or the kidney update.
We don't know exactly the reason.
The coordination chemistry is a little different, though.
May contribute to this.
So.
Because the, in copper,
the copper chelation of DOTA.
After this one.
So DOTA is a very good chelator for Indian
and Ghanian.
Very good chelator.
In terms of the copper 64 mentioned,
specifically DOTA is not an optimal chelator
for copper 64.
The reason for that is,
once it's get in the bloodstream,
and some of the enzymes will compete
with the copper 64.
So that's why, I don't know if,
if you've been to my first talk,
we talked about the copper 64,
with DOTA and with NODA.
And you can see some of the very high
normal organ accumulations there.
That's because for some of the enzymes
are coordinated with the copper 64.
But when you switch to NODA,
it's very stable.
That case is very stable.
And then, easily, through the
by distribution comparison,
you can see there's no,
you know, the normal organ accumulation
very, very low.
Less than 1% in that case.
But for,
for the Indian and the Ghanian,
DOTA has been a very good chelator for both.
Thank you.
Any more questions?
All right, so I think we can.

